CSL Stock | Analysis for April 2026, Price & Rating

CSL

ASX:CSL

$ 139,19

$-1,04 (-0,74%)

139,19 $

$-1,04 (-0,74%)

End-of-day quote: 04/10/2026

CSL Stock Value

The analyst rating for CSL is currently Outperform.

Outperform

CSL Company Info

EPS Growth 5Y

8,62%

Market Cap

$66,78 B

Long-Term Debt

$13,94 B

Quarterly earnings

05/19/2026 (E)

Dividend

$4,09

Dividend Yield

2,94%

Founded

1916

Industry

Health Care

Country

Australia

Website

CSL

ISIN Number

AU000000CSL8

Website

http://www.csl.com.au

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

$199,22

43.13%

Last Update: 04/11/2026

Analysts: 16

Highest Price Target $264,28

Average Price Target $199,22

Lowest Price Target $154,37

In the last five quarters, CSL’s Price Target has fallen from $463,83 to $308,03 - a -33,59% decrease. Fiveteen analysts predict that CSL’s share price will increase in the coming year, reaching $199,22. This would represent an increase of 43,13%.

Top growth stocks in the health care sector (5Y.)

What does CSL do?

CSL Limited (CSL), a biotechnology company, specializes in developing and delivering innovative medicines to save lives and improve the quality of life for individuals with serious health conditions. The company focuses primarily on the development and distribution of therapies derived from human plasma, recombinant proteins, and advanced biotherapeutics, addressing unmet medical needs in therapeutic areas such as immunology, hematology, cardiovascular and metabolic diseases, respiratory conditi...

Business Segments

The company operates through several distinct business segments, each contributing to the overall goals and mission of the company while addressing specific therapeutic areas and patient needs. The primary business segments include CSL Behring, CSL Seqirus, and CSL Vifor.

CSL Behring: This segment specializes in the manufacturing, marketing, and distribution of human plasma-derived and recombinant products. CSL Behring focuses on treatments for patients with rare and serious diseases, including various immune deficiencies and bleeding disorders. The segment is pivotal in providing life-saving therapies that ensure better health outcomes for individuals facing these challenging conditions.

CSL Seqirus: A leader in influenza vaccines and related products, CSL Seqirus is dedicated to combating seasonal and pandemic influenza viruses. The company manufactures a wide range of flu vaccines and offers pandemic services to government entities, ensuring preparedness during health crises. The segment places a strong emphasis on research and development to innovate new vaccines and improve existing formulations.

CSL Vifor: Acquired in 2022, CSL Vifor enhances the company’s portfolio in iron deficiency and nephrology. It develops and markets therapeutic products designed to treat conditions related to iron deficiency, which is crucial for patient populations, including those requiring dialysis and those with chronic kidney disease. This acquisition has allowed CSL to broaden its therapeutic reach and strengthen its position in the healthcare market.

Business Strategy

The company embraces a long-term strategy focused on enhancing patient health and achieving sustainable growth. Central to this strategy is the commitment to innovation, efficiency, and transparency. The company's strategic framework includes the following core elements:

Focus on Core Therapeutic Areas: CSL maintains a concentrated approach by prioritizing research and development in its core areas, such as immunology, hematology, and respiratory diseases. This focus allows the company to allocate resources effectively and drive advancements in critical fields.

Innovation and Technology: Emphasizing technological advancements and continuous innovation is vital for CSL. The company actively seeks to improve its product offerings through R&D initiatives and partnerships. The integration of connected healthcare technologies aims to enhance patient experiences and outcomes.

Digital Transformation: Recognizing the importance of digital tools in modern healthcare, CSL is investing in digital transformation initiatives aimed at improving operations and customer engagement. This transformation focuses on utilizing data analytics, enhancing patient systems, and optimizing supply chain processes.

People-Centric Strategy: At the heart of CSL's strategy is its workforce, with a commitment to fostering a culture that values diversity, collaboration, and purpose-driven work. The company applies comprehensive programs for talent development, ensuring that employees are equipped to meet the challenges of the future and contribute to the company’s mission of delivering innovative therapies to patients.

Products and Services

The company offers a diverse array of products and services that cater to various medical needs. The product portfolio is designed to support patients with serious and life-threatening conditions:

Plasma-Derived Therapies: One of the cornerstones of CSL Behring’s offerings, these therapies are crucial for treating patients with immune deficiencies and bleeding disorders. The company’s plasma-derived products include immunoglobulins, clotting factors, and albumin, all derived from human plasma donations.

Recombinant Protein Products: This includes cutting-edge therapies that utilize advanced biotechnology to produce proteins for therapeutic use. These products are vital for conditions such as hemophilia and specific genetic disorders, enhancing treatment outcomes through targeted therapies.

Vaccines and Pandemic Preparedness: CSL Seqirus develops a series of influenza vaccines that cater to various age groups and health conditions. The segment also provides consulting and support services to governments regarding pandemic readiness, ensuring communities are equipped to handle viral outbreaks effectively.

Iron Deficiency Therapeutics: Through CSL Vifor, the company produces a range of treatments specifically designed to address iron deficiency anemia. This includes intravenous iron therapies that are essential for patients with chronic kidney disease and those undergoing dialysis.

Research and Development Initiatives: CSL continually invests in R&D to discover and develop new therapies. This includes exploring novel treatment modalities, such as gene and cell therapies, demonstrating its commitment to advancing healthcare solutions.

Geographical Markets Served

The company operates on a global scale, serving patients and healthcare providers in numerous geographical markets. The company has a strong presence in established markets such as North America, Europe, and Asia Pacific. Additionally, CSL is expanding into emerging markets where there is an increasing demand for biopharmaceutical solutions. The global footprint allows CSL to leverage diverse market opportunities while adhering to local regulations and healthcare requirements.

Recent Acquisitions

The acquisition of Vifor Pharma Ltd on August 9, 2022, is a significant milestone for CSL. This strategic acquisition has allowed CSL to expand its capabilities in treating iron deficiency and nephrology, ultimately enhancing its therapeutic portfolio. By integrating Vifor’s products and expertise, CSL aims to address a wider range of health conditions and improve patient outcomes.

Seasonality

CSL’s operations may experience seasonality, particularly within the influenza segment as demand fluctuates with seasonal outbreaks. The company typically prepares for increased vaccine production leading into flu season, while ensuring consistent supply and distribution throughout the year to meet varying patient needs.

Customers

The company serves a diverse array of customers, including healthcare providers, hospitals, and patients across its various product and service lines. The customer base encompasses a wide spectrum of industries within healthcare, where CSL’s innovative therapies address critical needs across therapeutic areas.

Sales and Marketing

The company employs a multi-faceted approach to marketing and distribution, tailored to specific market segments. The company uses both direct sales force and partnerships with distributors to reach a wide range of clients effectively. Marketing efforts focus on building a strong brand presence, educating healthcare providers about product benefits, and engaging with patient communities to enhance awareness and access to therapies.

History

CSL Limited was founded in 1916. The company was incorporated in 1991.

CSL Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Industry Revenues:** - Biopharmaceuticals: 70% - Vaccines: 20% - Blood Plasma Derivatives: 10% **TOP 3 Markets:** - USA: 45% - Europe: 30% - Asia-Pacific: 15% CSL Limited generates the majority of its revenue from the biopharmaceutical industry, which accounts for approximately 70% of total reve...

At which locations are the company’s products manufactured?

**Production sites of CSL Limited:** 1. **Australia:** Headquarters in Melbourne, with significant production facilities. 2. **USA:** Several production sites, including in Kankakee, Illinois. 3. **Germany:** Production facility in Marburg. 4. **Switzerland:** Production site in Bern. 5. **United K...

What strategy does CSL pursue for future growth?

**Focus on Research and Development:** 10% of revenue (2024) **Planned investments in production capacities:** 1.5 billion USD (2025) CSL Limited pursues a growth strategy that is heavily focused on research and development (R&D). The company invests around 10% of its revenue in R&D to dev...

Which raw materials are imported and from which countries?

**Main raw materials:** Plasma, human albumin, immunoglobulins **Main supplying countries:** USA, Germany, China CSL Limited is a leading biotechnology company specializing in the development and production of products derived from human plasma. The key raw material for CSL is plasma, which is us...

How strong is the company’s competitive advantage?

**Market share in the biopharmaceutical sector:** 20% (estimated 2025) **Research & Development (R&D) expenses:** 10% of revenue (2024) **Patents and intellectual property:** Over 1,000 active patents (2025) CSL Limited has a significant competitive advantage in the biopharmaceutical se...

What is the share of institutional investors and insider buying/selling?

**Institutional investor share:** 55% (estimated for 2025) **Insider purchases/sales:** No significant insider transactions in the past year The institutional investor share in CSL Limited is approximately 55%, indicating that a large portion of the shares are held by major investment funds, pensio...

What percentage market share does CSL have?

**Market share of CSL Limited:** Approx. 20% (2025, estimated) **Main competitors and their market shares:** 1. **Grifols S.A.:** 15% 2. **Takeda Pharmaceutical Company Limited:** 12% 3. **Octapharma AG:** 10% 4. **Kedrion Biopharma:** 8% 5. **Biotest AG:** 5% **Moat of CSL Limited:** CSL Limited...

Is CSL stock currently a good investment?

**Revenue growth:** 10% (2024) **Research and development expenditure:** 1.2 billion USD (2024) **Market share in the field of plasma products:** 30% (2024) CSL Limited recorded a revenue growth of 10% in 2024, driven by strong demand for its biopharmaceutical products. The company continues to inv...

Does CSL pay a dividend – and how reliable is the payout?

**Dividend yield:** 1.5% (estimated for 2025) **Dividend history:** Continuous distribution over the past years CSL Limited has regularly paid dividends to its shareholders in the past. The dividend yield is currently estimated at 1.5% for the year 2025. The company has a long tradition of divi...

New support ticket

Explore

CSL Stock Value

CSL Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does CSL do?

CSL Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

CSL Stock Value

CSL Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does CSL do?

CSL Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.